ArticleFrontiers in oncology2025
Role of ADME genes in breast cancer prognosis: an analysis of risk scoring models based on multi-omics data.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fibroblast-derived HSD11B1 deficiency drives lung cancer in never-smokers through steroid metabolic imbalance.NPJ precision oncology · 2026Article
- A lactylation-related gene signature predicts metastasis and prognosis in breast cancer.Scientific reports · 2025Article
- A lipid metabolism-related gene signature for risk stratification and prognosis prediction in patients with breast cancer.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) is a significant malignancy characterized by a high global incidence and a propensity for recurrence. Absorption, distribution, metabolism, and excretion (ADME) genes comprise a collection of genes that participate in the drug ADME. Understanding the role and prognostic value of ARGs (ADME related genes) in BC advancement is critical for personalized therapy. Therefore, an ARPS (ADME related prognostic signature) was created in this study to examine the clinical implications of ARGs in patients with BC. Methods: A multi-omics investigation of ADME-related genes in BC was conducted using bulk RNA sequencing, single-cell RNA sequencing, and spatial transcriptome data. According to the expression profiles of ADME-related differentially expressed genes (DEGs), the ARPS was calculated, and all patients were stratified based on their risk scores. A prediction model was then created using Cox regression and stepAIC analyses. This model divided all patients into HR (High risk) and LR (Low risk) groups following the median risk score. Bioinformatics analyses were conducted to estimate the risk signature's predictive capacity. Results: This study identified five ARGs (SLC7A5, HSD11B1, ADHFE1, GSTM2, and TAP1) correlated with BC prognosis. The risk signature in the TCGA-BRCA, METABRIC, and GSE58812 cohorts revealed robust predictive accuracy for 1-, 3-, and 5-year survival. Compared to the gene signature alone, the nomogram integrating the ARPS and clinical parameters demonstrated improved prognostic performance. Immune infiltration analysis revealed a high level of immune checkpoint related gene expression and immune score in patients with ARPS LR, suggesting potential implications for immunotherapy responses. Conclusion: The findings highlight the prognostic significance of ARPS in BC and its potential utility in guiding personalized treatment strategies. Combining ARPS with clinical parameters enhances prognostic accuracy and may help patients with BC make clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.